Search

Your search keyword '"Miranda-Palma B"' showing total 17 results

Search Constraints

Start Over You searched for: Author "Miranda-Palma B" Remove constraint Author: "Miranda-Palma B"
17 results on '"Miranda-Palma B"'

Search Results

Catalog

Books, media, physical & digital resources

3. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

4. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial

5. Liraglutide and Renal Outcomes in Type 2 Diabetes

6. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

7. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

8. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial

9. Efficacité et tolérance de l’insuline dégludec administrée selon un schéma flexible versus insuline dégludec ou insuline glargine administrées selon un schéma fixe dans le diabète de type 1 : résultats de l’essai « BEGIN: Flex T1 », un essai randomisé en treat-to-target de 26 semaines, et de son extension à 52 semaines

10. O48 Chez des diabétiques de type 1, l’insuline dégludec administrée une fois/jour selon un schéma flexible assure un contrôle glycémique et une tolérance similaire à une administration quotidienne selon un schéma à heure fixe

11. 40 EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

12. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

13. 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

14. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.

15. Insulin degludec: a novel ultra-long-acting basal insulin for use in Type 1 and 2 diabetes.

16. Health care models for treatment and management of diabetes. Introduction.

17. A randomized trial of two irremovable off-loading devices in the management of plantar neuropathic diabetic foot ulcers.